期刊
JOURNAL OF ETHNOPHARMACOLOGY
卷 173, 期 -, 页码 370-382出版社
ELSEVIER IRELAND LTD
DOI: 10.1016/j.jep.2015.07.018
关键词
Acute ischemic stroke (AIS); Buyang Huanwu decoction (BHD); Tianma Gouteng decoction (TGD); Shengyu decoction (SYD); Xuefu Zhuyu decoction (XZD); functional modules and genetic networks; genome-wide transcriptome analysis; neurogenesis; micro-positron emission tomography (mu PET); syndrome differentiation
资金
- National Science Council (NSC), R.O.C. [NSC-101-2320-B-077-005-MY3, NSC101-2320-B-010-059-MY3, NSC101-2627-B-010-003, NSC101-2321-B-010-011]
- National Research Institute of Chinese Medicine [NRICM102-DBCM01-B1, NRICM101-DBCM08, NRICM100-DBCM09, NRICM99-DBCM09, MOHW103-NRICM-C-315-122401, MOHW104-NRICM-M-315-113401]
- National Health Research Institutes [NHRI-EX102-10254SI]
- National Yang-Ming University (Ministry of Education)
- UST-UCSD International Center for Excellence in Advanced Bioengineering - Taiwan NSC I-RiCE Program [NSC101-2911-I-009-101]
Ethnopharmacological relevance: Four traditional Chinese herbal remedies (CHR) including Buyang Huanwu decoction (BHD), Xuefu Zhuyu decoction (XZD), Tianma Gouteng decoction (TGD) and Shengyu decoction (SYD) are popular used in treating brain-related dysfunction clinically with different syndrome/pattern based on traditional Chinese medicine (TCM) principles, yet their neuroprotective mechanisms are still unclear. Materials and methods: Mice were subjected to an acute ischemic stroke to examine the efficacy and molecular mechanisms of action underlying these CHR. Results: CHR treatment significantly enhanced the survival rate of stroke mice, with BHD being the most effective CHR. All CHR were superior to recombinant tissue-type plasminogen activator (rt-PA) treatment in successfully ameliorating brain function, infarction, and neurological deficits in stroke mice that also paralleled to improvements in blood-brain barrier damage, inflammation, apoptosis, and neurogenesis. Transcriptome analyses reveals that a total of 774 ischemia-induced probe sets were significantly modulated by four CHR, including 52 commonly upregulated genes and 54 commonly downregulated ones. Among them, activation of neurogenesis-associated signaling pathways and down-regulating inflammation and apoptosis pathways are key common mechanisms in ischemic stroke protection by all CHR. Besides, levels of plasma CX3CL1 and S100a9 in patients could be used as biomarkers for therapeutic evaluation before functional recovery could be observed. Conclusion: Our results suggest that using CHR, a combinatory cocktail therapy, is a better way than rt-PA for treating cerebral ischemic-associated diseases through modulating a common as well as a specific group of genes/pathways that may partially explain the syndrome differentiation and treatment principle in TCM. (C) 2015 Elsevier Ireland Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据